SCHEMBL26567770

SCHEMBL26567770

Cc1ccc2sc(C3CC4(CC(NC(=O)CC5CS(=O)(=O)C5)C4)C3)nc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.36
▸ UBE2M P61081 3/20 0.33
▸ DCUN1D1 Q96GG9 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ ALDH1A1 P00352 5/20 0.33
▸ HDAC4 P56524 2/20 0.33
▸ KDM4E B2RXH2 4/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NPC1 O15118 4/20 0.31
▸ SMN1; SMN2 Q16637 3/20 0.31
▸ RAB9A P51151 3/20 0.31
▸ NFKB1 P19838 2/20 0.31
▸ NFKB2 Q00653 2/20 0.31
▸ RELA Q04206 2/20 0.31
▸ GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26185598 0.89 NPC1 (0.41) MAPTLMNATP53ALDH1A1KMT2A
SCHEMBL29700405 0.89 NPC1 (0.41) MAPTLMNATP53ALDH1A1KMT2A
SCHEMBL26567751 0.86 DYRK1A (0.38) DYRK1AUBE2MDCUN1D1MAPTLMNA
SCHEMBL26567777 0.85 DYRK1A (0.35) DYRK1AUBE2MDCUN1D1MAPTLMNA
SCHEMBL29700392 0.81 NPC1 (0.40) MAPTLMNAALDH1A1KDM4EKMT2A
SCHEMBL26185597 0.81 NPC1 (0.40) MAPTLMNAALDH1A1KDM4EKMT2A
SCHEMBL26567756 0.81 DYRK1A (0.36) DYRK1AUBE2MDCUN1D1MAPTLMNA
SCHEMBL26567801 0.80 FASN (0.37) DYRK1AUBE2MDCUN1D1MAPTLMNA
SCHEMBL26567817 0.79 UBE2M (0.34) DYRK1AUBE2MDCUN1D1MAPTLMNA
SCHEMBL26567808 0.76 DYRK1A (0.38) DYRK1AUBE2MDCUN1D1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, NR1I3, NR1H4 DYRK1A 4673/4885UBE2M 3500/4885DCUN1D1 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback